This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2008 by University Hospital, Limoges.
Recruitment status was:  Recruiting
Information provided by:
University Hospital, Limoges Identifier:
First received: September 14, 2005
Last updated: December 30, 2008
Last verified: December 2008

This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months

Condition Intervention Phase
Cancer Drug: warfarine - low molecular heparin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study

Resource links provided by NLM:

Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis :
  • Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy

Secondary Outcome Measures:
  • - Detection of asymptomatic thrombosis related to implantable device estimated by a systematic echo-doppler. -
  • - Frequency of other symptomatic venous thromboembolic events between 3 groups.
  • Comparison of thrombosis prophylaxis by LMWH with warfarin at low dose
  • -Costs in the 3 strategies
  • - Tumoral response to chemotherapy in the 3 groups.
  • - Overall survival in each group.

Estimated Enrollment: 420
Study Start Date: August 1999
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First line chemotherapy for solid tumor with:
  • Metastatic disease or
  • Involved nodes or
  • Unresectable tumor
  • Indication for Implantable device for central venous access
  • Potential survival > 3 months
  • ECOG performance status 0 to 2 (WHO)
  • Age between 18 and 75 years.
  • Social security guaranteed
  • Normal laboratory assessments (platelets> 100000/mm3, TP 60%, spontaneous TCA with M/T<1.5, TGO and TGP < 2xN, serum creatinin<120µmol/l)
  • Informed consent signed

Exclusion Criteria:

  • Inability to understand informed consent or interfering with compliance for treatment or protocol Anti-coagulant treatment -related criteria
  • Acute infectious endocarditis
  • History related with heparin allergy or thrombopenia due to heparin
  • Uncontrolled high blood pressure (systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg)
  • Hemorrhagic syndrome ongoing
  • Patient with platelet inhibitors treatment
  • Chronic, daily treatment with anti-coagulant therapy (LMWH or AVK), use as preventive or curative level
  • Patient with liver failure (TP<60%) or renal insufficiency (creatinin clearance< 20 ml/mn)
  • Women with pregnancy and lactating Pathology-related criteria
  • deep venous thrombosis history or pulmonary embolism (< 6 months)
  • Clinical suspicious of brain metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00199602

Contact: Nicole TUBIANA-MATHIEU, MD +33(0) 555 056 396

Oncologie Médicale Recruiting
Limoges, France, 87000
Contact: Nicole TUBIANA-MATHIEU, MD         
Principal Investigator: Nicole TUBIANA-MATHIEU, MD         
Sponsors and Collaborators
University Hospital, Limoges
Principal Investigator: Nicole TUBIANA-MATHIEU, MD University Hospital, Limoges
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Madame Marie SENGELEN/Directrice des Affaires Médicales et de la recherche Clinique, Chu Limoges Identifier: NCT00199602     History of Changes
Other Study ID Numbers: I99006
Study First Received: September 14, 2005
Last Updated: December 30, 2008

Additional relevant MeSH terms:
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017